"Moreover, this appeared to be associated with increasing PD-L1 scores, although it should be noted that these tested TPS, and not CPS,"
it is biased and a little misleading. such as In advanced-stage NSCLC, tumor proportion score (TPS) is typically used to predict the efficacy of immune checkpoint inhibitors (ICIs). Nevertheless, in other cancer types, the combined positive score (CPS).
"Moreover, this appeared to be associated with increasing PD-L1...
-
- There are more pages in this discussion • 253 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.5¢ | 41.0¢ | $1.132M | 2.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 15565 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 246989 | 7 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |